COMPANY PROFILE

Encellin

Explore full profile

Encellin is developing a novel thin-film cell encapsulation device for cell-based therapeutics

Livermore, United StatesFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Encellin

Encellin is a biotechnology company developing a proprietary cell encapsulation technology to deliver cell-based therapies for chronic diseases. The company's approach involves a novel thin-film cell encapsulation device that protects and houses cells, enabling them to function as 'living medicines' within the body. This technology is designed to treat conditions where cells are missing, damaged, or diseased by transplanting functional cells.

Encellin's initial focus is on endocrine disorders, with the goal of providing long-term treatment solutions and potentially curative therapies. The company's business model is centered on advancing its technology through clinical trials and securing regulatory approval. Having recently closed a significant financing round of $9.9 million, Encellin is well-positioned to further its research and development efforts. The company was founded based on technology developed at the University of California, San Francisco.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Livermore, United States
Employees: 8
Open positions: None listed
Dealroom signal: 72.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Sep 2023	$9.9M	$40M	Khosla Ventures · Y Combinator	↗
SEED✓Equity / VC	Aug 2021	$5.9M	$24M	Sand Hill Angels · SV Latam Capital · Khosla Ventures · Y Combinator	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Encellin website traffic

Latest recorded traffic for Encellin is 230 monthly website visits, down 86.5% over the last three months. Encellin's team grew 0% over the past year.

Latest monthly visits230 3-month web change-86.5% 1-year team growth0%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational	15	$63M	$152M
DADiagen AIAI-driven protein design platform for health science	Vancouver, Canada	Operational
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired
DBDelve BioProviding Molecular Insights for the Precision Care of the Sickest Patients	Boston, United States	Operational
CBCurve BiosciencesUnlocking the right data to help patients with chronic disease on their decades-long journey	Mountain View, United States	Operational
HLHangzhou Dunen Medical Testing LaboratoryA clinical precision medication guidance service provider	Hangzhou, China	Operational
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational